Country: Canada
Language: English
Source: Health Canada
METFORMIN HYDROCHLORIDE
MELIAPHARM INC
A10BA02
METFORMIN
500MG
TABLET
METFORMIN HYDROCHLORIDE 500MG
ORAL
100/500
Prescription
BIGUANIDES
Active ingredient group (AIG) number: 0101773001; AHFS:
CANCELLED POST MARKET
2014-06-25
PRODUCT MONOGRAPH PR METFORMIN (Metformin tablets BP as Metformin Hydrochloride) 500MG TABLETS ANTIHYPERGLYCEMIC AGENT MELIAPHARM INC . DATE OF PREPARATION: 6111 Royalmount Ave, Suite #100 March 16, 2010 Montreal, Quebec H4P 2T4 Control # 136739 2 PRODUCT MONOGRAPH PR METFORMIN (Metformin tablets BP as Metformin Hydrochloride) 500 mg THERAPEUTIC CLASSIFICATION Anti hyperglycemic Agent ACTIONS AND CLINICAL PHARMACOLOGY Metformin is a biguanide derivative producing an antihyperglycemic effect which can only be observed in man or in the diabetic animal and only when there is insulin secretion. Metformin, at therapeutic doses, does not cause hypoglycemia when used alone in man or in the nondiabetic animal, except when using a near lethal dose. Metformin has no effects on the pancreatic beta cells. The mode of action of metformin is not fully understood. It has been postulated that metformin might potentiate the effect of insulin or that it might enhance the effect of insulin on peripheral receptor sites. This increased sensitivity seems to follow an increase in the number of insulin receptors on cell surface membranes. Metformin absorption is relatively slow and may extend over about 6 hours. The drug is excreted in urine at a high renal clearance rate of about 450 mL/min. The initial elimination of metformin is rapid with a half-life varying between 1.7 and 3 hours. The terminal elimination phase accounting for about 4 to 5% of the absorbed dose is slow with a half-life between 9 and 17 hours. Metformin is not metabolized. Its main sites of concentration are the intestinal mucosa and the salivary glands. The plasma concentration at steady state ranges about 1 to 2 µg/mL. Certain drugs may potentiate the effects of metformin (see PRECAUTIONS). 3 A comparative bioavailability study of metformin 500 mg tablets was performed. Pharmacokinetic and bioavailabilty data were measured in 22 volunteers in the _fasting _ state and _fed state. _ The results can be summarized as follows: SUMMARY OF COMPARATIVE BIOAVAILABILITY DA Read the complete document